Table 3.
Drugs used for the initial pharmacological treatment of patients with hormonally functional PHAEO/PGL either alone or in combination.
| Drugs | Patients, n (%) |
|---|---|
| α-Adrenoceptor blockers (n = 260) | |
| Phenoxybenzamine | 161 (61.9) |
| Doxazosin | 27 (10.4) |
| Prazosin | 18 (6.9) |
| Terazosin | 7 (2.7) |
| Unknown | 47 (18.1) |
| β-Adrenoceptor blockers (n = 111) | |
| Metoprolol | 46 (41.4) |
| Atenolol | 18 (16.2) |
| Propranolol | 12 (10.8) |
| Bisoprolol | 3 (2.7) |
| Acebutolol | 1 (0.9) |
| Unknown | 31 (27.9) |
| Combined α- and β-adrenoceptor blockers (n = 9) | |
| Labetalol | 7 (77.8) |
| Carvedilol | 2 (22.2) |
| CCBs (n = 31) | |
| Amlodipine | 19 (61.3) |
| Diltiazem | 6 (19.4) |
| Verapamil | 3 (9.7) |
| Nifedipine | 2 (6.5) |
| Nicardipine | 1 (3.2) |
| ACE inhibitors (n = 13) | |
| Lisinopril | 12 (92.3) |
| Enalapril | 1 (7.7) |
| ARBs (n = 8) | |
| Valsartan | 4 (50) |
| Losartan | 3 (37.5) |
| Unknown | 1 (12.5) |
| Metyrosine (n = 7) | |
| Clonidine (n = 1) |
ACE inhibitors = angiotensin-converting enzyme inhibitors; ARBs = angiotensin II receptor blockers; CCBs = calcium channel blockers; metyrosine = α-methyl-ρ-tyrosine; PHAEO/PGL = phaeochromocytoma and paraganglioma.